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Abstract The impact of advances in nanotechnology is
particularly relevant in biodiagnostics, where nanoparticle-
based assays have been developed for specific detection of
bioanalytes of clinical interest. Gold nanoparticles show easily
tuned physical properties, including unique optical properties,
robustness, and high surface areas, making them ideal
candidates for developing biomarker platforms. Modulation
of these physicochemical properties can be easily achieved by
adequate synthetic strategies and give gold nanoparticles
advantages over conventional detection methods currently
used in clinical diagnostics. The surface of gold nanoparticles
can be tailored by ligand functionalization to selectively bind
biomarkers. Thiol-linking of DNA and chemical functional-
ization of gold nanoparticles for specific protein/antibody
binding are the most common approaches. Simple and
inexpensive methods based on these bio-nanoprobes were
initially applied for detection of specific DNA sequences and
are presently being expanded to clinical diagnosis.
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Abbreviations
DNA Deoxyribonucleic acid
ssDNA Single-stranded deoxyribonucleic acid
RNA Ribonucleic acid
AuNP Gold nanoparticle
AFM Atomic force microscopy
SNP Single-nucleotide polymorphism
SPR Surface plasmon resonance
Introduction
Nanodiagnostics can be defined as the use of nano-sized
materials, devices or systems for diagnostics purposes. It is
a burgeoning field as more and improved techniques are
becoming available for clinical diagnostics with increased
sensitivity at lower cost [1]. Biological tests measuring the
presence or activity of selected analytes become quicker,
more sensitive and more flexible when nanoscale particles
are put to work as tags or labels, with numerous advantages
over more traditional procedures, for example fluorescence
and chemiluminescence technology. Nanoparticles have
high surface areas and unique physicochemical properties
that can be easily tuned, making them ideal candidates for
developing biomarker platforms.
In this review we will focus on gold nanoparticles
(AuNPs) used as basis for the development of methodologies
suitable for application in clinical diagnosis. AuNP-based
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diagnostics can be broadly divided in three different
approaches:
1. utilization of the AuNP color change upon aggregation,
the best characterized example being AuNPs function-
alized with ssDNA capable of specifically hybridizing
to a complementary target for the detection of specific
nucleic acid sequences in biological samples [2];
2. use of AuNPs as a core/seed that can be tailored with a
wide variety of surface functionalities to provide highly
selective nanoprobes for diagnosis [3]; and
3. utilization of AuNPs in electrochemical based methods
that can be coupled with metal deposition for signal
enhancement [4].
The last approach was recently the theme of excellent
reviews [5, 6] and will not be dealt with in this critical
review. The first approach based on color changes is by far
the most developed in terms of clinical diagnosis and
several application examples will be presented. The second
approach shows great potential for future applications and
future trend lines will be highlighted.
Synthesis and properties of AuNPs
Gold nanoparticles have been widely studied for their unique
optical properties arising from their surface plasmon reso-
nance (SPR) [7]. AuNPs have exceptionally high absorption
coefficients, allowing higher sensitivity in optical detection
methods than conventional dyes. Typically, colloidal
solutions of spherical AuNPs are red with the SPR band
centered at ca. 520 nm. This band is weakly dependant on
the size of the particle and the refractive index of the
surrounding media [8–10], but strongly changes with shape
[8, 10, 11], and inter-particle distance [12]. The morphol-
ogy and surface chemistry of nanoparticles is usually
controlled by using appropriate synthetic methods; these
will be discussed briefly in the end of this section.
The strong absorption of AuNPs has been advantageous-
ly used in colorimetric detection of analytes, either by
inducing aggregation of AuNPs in the presence of specific
analytes [13–18], or by measuring changes in the refractive
index of the AuNPs environment, due to adsorption of
biological analytes [19]. The great enhancement of electro-
magnetic field at the surface of AuNPs by interaction with
electromagnetic radiation offers other interesting optical
properties with great potential for biodiagnostic assays. For
instance, AuNPs have been used for single-molecule
detection by surface-enhanced Raman spectroscopy (SERS)
[20]. In addition to the optical properties of AuNPs, their
catalytic activity has also been used as a means of
developing highly sensitive detection methods, for example
by electrochemical detection that can be coupled with
enzyme assays [5, 6, 21] and/or with metal deposition for
signal enhancement [4].
The successful utilization of AuNPs in biological assays
relies on the availability of synthetic methods generating
nanoparticles with the desired characteristics, namely high
solubility in water, and adequate morphology, size disper-
sion, and surface functionalities. Numerous synthetic
strategies for the preparation of AuNPs have been reported
[22–24]. Most commonly, AuNPs are synthesized by
chemical or electrochemical reduction of a gold(III)
precursor compound in the presence of a capping agent,
i.e. a compound able to bind to the nanoparticle surface
blocking its growth beyond the nanometer range and
stabilizing the colloid in the particular solvent used. Control
over the shape and size of the AuNPs is usually achieved
through the careful selection of the experimental condi-
tions, namely reducing agent, reaction time, temperature,
and capping agent. A common approach is to use capping
agents with strong affinity for gold, e.g. thiol capping
agents. This allows the synthesis of AuNPs with good size
dispersion but usually only soluble in organic solvents [25]
requiring an additional step of extraction of the particles
into water. In addition, exchange of strongly binding
capping agents is usually cumbersome, which makes this
type of AuNP less versatile for biological applications.
Due to its simplicity and high yield, the most commonly
used method for preparation of spherical AuNPs for
biological assays is the citrate reduction method of
Turkevich et al. [26]. The use of citrate as a capping agent
is very convenient due to its easy post-synthesis treatment,
since it can be easily replaced by other capping agents, e.g.
thiol capping agents, bearing an appropriate functionality
for binding of the biological analyte of interest. Size control
is reasonable, and recent modifications have allowed not
only for better size distribution of the AuNPs, but also
control of their size within the 9–120 nm range [27].
Several other methods for improvement of size dispersion
of spherical AuNPs have been reported [28, 29]. In
addition, several methods have been published for prepa-
ration of water-soluble AuNPs with SPR bands in the near
infrared [30]. This type of AuNP is quite promising for
biological applications, allowing the use of AuNPs in
biological fluids without interference from absorption of
other biological molecules. Furthermore, the simultaneous
use of AuNPs absorbing at different wavelengths might
allow multiplexed analysis.
Functionalization of AuNPs
Functionalization of Au-NPs involves the use of bifunc-
tional ligands in which a moiety is used for anchorage to
the particle while the other is directed to the outer-surface
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for specific interaction with biomolecules. For example,
thiol-modified oligonucleotides have been used to function-
alize AuNPs for specific detection of nucleic acid sequen-
ces in biological samples (see below).
Functionalization of Au-NPs with biomolecules other than
nucleic acids has also been used in order to develop
methodologies suitable for clinical diagnostics. These include:
& antibodies for signal enhancement in immunoassays
[21, 31–34];
& carbohydrate functionalization to study specific molec-
ular interactions [35, 36]; and
& surface functionalization with ligands that can be
tailored for specific protein binding [3, 37] or direct
binding of peptides and proteins to the Au-nanoparticle
surface [18, 38, 39].
The specific interaction between biological pairs has also
been widely used, e.g. biotin–streptavidin [40, 41] and Ni-
NTA–histidine tail [42, 43].
Glyconanoparticles
Carbohydrate functionalized nanoparticles (“glyconanopar-
ticles”) have the advantage of increasing the specific inter-
actions between glycans and lectins for biosensing applications
[44–46]. Compared with biotin–streptavidin, the carbohy-
drate–protein interaction is relatively weak but can be
successfully enhanced by multivalent interactions—the so-
called “cluster glycoside effect” [47]. These multivalent
carbohydrate–ligand/protein interactions were successfully
used by Tsai et al [46] in a rapid, selective, and quantitative
detection method for the carbohydrate-binding protein con-
cavalin A. Penadés et al. have developed a glyconanotech-
nology strategy to study and evaluate carbohydrate–
carbohydrate and carbohydrate–protein interactions, enabling
the establishment of models for carbohydrate-mediated
biological processes [35]. Multifunctional glyconanoparticles
containing lactose were prepared as a possible platform for
carbohydrate-based anticancer vaccines, with the potential for
tailoring polyvalent anticancer vaccines and drug-delivery
carriers [36]. Even though glyconanoparticles are simple and
flexible to prepare and have several interesting physical,
chemical, and biological properties, their utilization in clinical
diagnosis is still under development.
Monolayer-protected clusters for protein binding
Rotello and co-workers have performed seminal work on
monolayer-protected clusters (MPCs) bearing organic func-
tions such as multivalent and non-covalent recognition
elements [37]. The thiolated ligands used for gold nano-
particle functionalization (cationic, anionic, hydrophobic,
etc.) generate a plethora of stable single (MPCs) or mixed
(MMPCs) Au-nanoprobes, the latter often including groups
like oligo(ethylene glycol) and poly(ethylene glycol) to
improve water-solubility and to decrease non-specific
protein binding [48, 49]. Recently, utilization of MMPCs
in a sensor array based on fluorescence quenching was
reported [3]. The system explores a “chemical nose/tongue”
approach featuring selective receptors (instead of the more
common “lock–key” specific recognition procedures) to
detect, identify, and quantify protein targets. The robust
characteristics of its components (nanoparticles, polymers),
the simplicity of the method, and the tailoring possibilities
provided by nanoparticle-surface functionalization, make
this array an extremely promising approach to point-of-care
diagnosis.
Peptide-capped Au-nanoprobes
The tailoring of the gold nanoparticle’s surface by fabricat-
ing monolayer-protected nanoparticles was employed in the
rational design of peptide-capping ligands [38]. The
proposed combinatorial approach enables the synthesis of
exceptionally stable AuNPs with properties in aqueous
media that are modulated by the amino acid sequence of the
appended cysteine-terminated penta-peptide [39]. The
design strategy of these peptides combines a strong affinity
for gold (cysteine), the ability to self-assemble into a dense
layer that excludes water (amino acid residues with
hydrophobic side chains), and a hydrophilic terminus to
ensure solubility and stability in water [39]. This type of
nanoparticle-peptide probe has been successfully utilized in
a colorimetric kinase activity method [18] in which the
kinase-substrate can be identified by specific binding of
gold nanoparticles to the phosphorylated product immobi-
lized on a microarray [50]. This format allows a multi-
plexed approach and opens the possibility for application in
clinical diagnosis and drug discovery.
Specific DNA and RNA detection based on AuNPs
The use of thiol-linked ssDNA-modified gold nanoparticles
(herein designated Au-nanoprobes) for the colorimetric
detection of DNA targets represents an inexpensive and
easy to perform alternative to fluorescence or radioactivity-
based assays (Ref. [51] and references therein). In 1996,
Mirkin et al. [2] described the use of single-stranded
oligonucleotide targets that could be detected using two
different Au-nanoprobes such that each was functionalized
with a DNA-oligonucleotide complementary to one half of
the given target. The hybridization of the two Au-
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nanoprobes with the target resulted in the formation of a
polymeric network (cross-linking mechanism), which
brought the gold nanoparticles close enough to result in a
red to blue color change. This cross-linking mechanism,
where a nanoparticle is functionalized with several
identical ssDNA oligonucleotides, brings each nanoparticle
in close vicinity to several others through the specific
hybridization of the DNA strands. Therefore, the cross-
linking of multiple Au-nanoprobes allows for extensive
nanoparticle aggregation, and yields the observed colori-
metric change. In this system, the Au-nanoprobes were
oriented in a tail-to-tail arrangement—one probe function-
alized via a 5′-thiol bond and the other through a 3′-thiol
group [51–53]. Recently the same method was elegantly
expanded from specific detection of DNA sequences to a
real-time screening assay for endonuclease activity [54].
Following a parallel approach, we developed a simple,
easy-to-use and inexpensive assay based on a non-cross-
linking hybridization method, where aggregation of the Au-
nanoprobes is induced by an increasing salt concentration
[55, 56]. Our method consists in visual and/or spectropho-
tometric comparison of solutions before and after salt-
induced Au-nanoprobe aggregation—the presence of a
complementary target prevents aggregation and the solution
remains red; non-complementary/mismatched targets do not
prevent Au-nanoprobe aggregation, resulting in a visible
change of color from red to blue. The schematic diagram of
this “Au-nanoprobe method” shown in Fig. 1 highlights its
applications to clinical-derived samples [56]. This Au-
nanoprobe method was also used to detect eukaryotic gene
expression (RNA) without the need for retro-transcription
or PCR amplification steps [55]. The method was able to
specifically detect mRNA from as little as 0.3 μg of
unamplified total RNA, avoiding the RNA to cDNA
conversion step normally utilized by other methods.
We used AFM, a highly suitable technique for producing
high-quality images and measurements of individual bio-
molecules [57], for imaging in parallel to the above
described colorimetric detection system, to elucidate the
DNA recognition events occurring at the nanoscale, i.e.
hybridization of Au-nanoprobes to target double-stranded
DNA that had previously been heat denatured to a single-
stranded form. Complementary and non-complementary
target sequences were used to study the level of specific
interaction between the target and the Au-nanoprobes. This
furnished direct evidence of the mechanism involved in Au-
nanoprobe hybridization and enabled assessment of non-
specific interactions between the Au-nanoprobes and the
target [58]. An example image of the gold nanoparticles
bound to the complementary DNA strands is shown in
Fig. 2, in which a PCR-generated fragment from the β-
globin gene locus was hybridized with Au-nanoprobes
harboring a complementary DNA sequence. Analysis of a
large number of hybridization products strongly supported
hybridization to the complementary sequence as the
primary interaction with the Au-nanoprobes. Bui et al.
[59] have also used AFM to image aggregation caused by
specific hybridization of ssDNA-modified nanoparticles
with target ssDNA. The AFM clearly showed the aggre-
gates of NPs used, and the authors established a linear
Fig. 1 Au-nanoprobe assay
method. After DNA purification
from clinical samples, the Au-
nanoprobe method can be di-
rectly applied to the isolated
DNA or to an enzyme mediated
amplified product. The method
relies on visual comparison of
test solutions before and after
salt-induced Au-nanoprobe
aggregation. Blank, Au-
nanoprobe alone; Neg, negative
sample in the presence of non-
complementary DNA/RNA;
Pos, positive sample in the
presence of complementary
DNA/RNA; SNP/Mut, in the
presence of DNA harboring
SNP or single point mutation
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relationship between the diameter of the aggregates and the
concentration of target DNA in solution. However, the
actual hybridization was not directly visualized.
AuNPs-based clinical diagnostic methods
AuNPs in clinical immunoassays
Gold nanoparticles have found promising applications in
signal enhancement of the standard enzyme-linked immu-
nosorbent assays (ELISAs) where they can be conjugated
with the antibodies [60] or coupled with silver-enhancement
[61]. Recent examples include the development by Tanaka
et al. [60] of a novel enhancement for immunochromato-
graphic test strips where both the primary and the
secondary antibodies are conjugated with AuNPs. This
experimental set-up increased the limit of detection of the
chorionic gonadotropin hormone by an order of magnitude
to reach 1 pg mL−1. Sensing platforms have also been
developed based on fiber optic evanescent-wave sensors
functionalized with self-assembled gold colloids [62] or
using a Cy5-antibody-AuNP complex as the fluorescence
probe [32]. These sensing platforms may replace the
standard ELISA assay since they do not require a secondary
antibody and allow sensitivity increases of at least one
order of magnitude. The sensitivity of chemiluminescent
analysis of antibodies in clinical samples could also be
improved by using irregularly shaped AuNPs, which have
100-fold greater catalytic activity in comparison with
spherical AuNPs [34]. Anti-IgG derivatized with these
irregular AuNPs was used to determine successfully the
IgG content of human plasma samples. Electrochemical
approaches based on derivatization of electrodes with
AuNPs have recently been applied to the label-free
detection of the carcinoembryonic antigen (CEA) [33, 63].
The immunosensors obtained showed excellent reproduc-
ibility and stability [33], allowing batch fabrication [63].
The use of metal-enhanced fluorescence, a near-field effect
that can significantly enhance fluorescence signatures up to
fivefold, has found application in immunoassays through
silver nanoparticles [64, 65]. Application of AuNPs in this
field is a promising area under development [66]. For
further applications of signal-amplification technologies in
immunoassays and new generations of lateral-flow assays,
see Ref. [31] and references therein.
AuNP-based DNA-detection clinical assays
A recent development of the now traditional Au-nanoprobe
cross-linking method of Mirkin et al [2], is the bio-
barcode system, used for protein detection with attomolar
sensitivity. The method involves the capture of the analyte
with a magnetic particle featuring recognition elements,
followed by binding of a functionalized AuNP with a
second recognition agent and “barcode” (marker) DNA
strands. After magnetic separation of the sandwich com-
plex, the DNA barcodes are released and the DNA strands
detected and quantified using the a Au-nanoprobe sandwich
assay followed by silver enhancement [67, 68]. This
method was successfully used for measuring the concen-
tration of amyloid-β-derived diffusible ligands, a potential
Alzheimer’s disease marker present at extremely low concen-
trations (<1 pmol L−1) in the cerebrospinal fluid of affected
individuals [69].
The Au-nanoprobe method we developed has been
successfully applied to the detection of single nucleotide
polymorphisms (SNPs) and mutations associated with
disease or metabolic variation [70]. The technique facili-
tates characterization of individual genetic variability,
which has been associated with individual susceptibility to
several multifactorial diseases such as cancer, diabetes, and
also with individual response to therapeutics. A rather
successful application of the Au-nanoprobe method to
clinical diagnosis was in the rapid and sensitive detection
of Mycobacterium tuberculosis (the etiologic agent of
human tuberculosis) in clinical samples [56]. In order to
improve sensitivity and easily achieve quantification of
target DNA/RNA samples, the detection system was
directly integrated in an amorphous/nanocrystalline silicon
device, without the need to functionalize the glass surface
with the sequence of interest [71].
Other systems based on non-cross-linking DNA hybrid-
ization [17, 72, 73] have been described and applied to
detection and characterization of human SNP sequences. A
considerable increase in output signal and sensitivity can be
Fig. 2 Tapping mode AFM image of hybridization product of Au-
nanoprobes (yellow) and target DNA (blue strings). DNA is a PCR
product of the β-globin gene locus genomic region and the Au-
nanoprobes harbor a complementary ssDNA sequence. Image size
3 μm
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achieved by signal amplification by autometallography,
leading to an approximately 1000-fold increase of the
detection signal [74]; the scattered light is detected with a
specifically designed photosensor coupled with an imaging
system but with the inconvenience of more complicated
experimental set-up and expensive apparatus [17, 75].
Recently, an improvement in non-cross-linking DNA
hybridization for SNPs detection was described in which
SPR imaging allowed a limit of detection of 32 nmol L−1
(19 fmol) without temperature control in 5 min [76] making
this a promising method for point-of-care testing for SNPs.
A SPR platform was also used for sensitivity improvement
of detection of p53 cDNA at sub-attomole concentrations
using Au-nanoprobes, allowing detection of a 39-mer target
in 15 μL of a 1.38 fmol L−1 solution; this has important
promise for cancer diagnosis [77].
The double-probe cross-linking method developed by
Mirkin and collaborators [78] is considerably more specific
than the non-cross-linking mechanisms, as it uses two
probes, hence increasing the specificity of hybridization.
Furthermore, in this approach the temperature at which probe
hybridization occurs is tightly controlled, thus optimizing
specificity. However, this strategy makes use of expensive
apparatus and technology that might be difficult to imple-
ment at point-of-care. The non-cross-linking method, due to
use of a single probe, can in principle compete with other
currently available methods but at lower cost and with
greater simplicity, taking less than 30 min to complete. The
color change can be easily visualized with the naked eye,
thus rendering it suitable for point-of-care diagnostics.
Only very few Au-NP-based strategies have proven
suitable for direct use on biological samples in clinical
diagnostics. Most AuNP-based methods are rapid and easy
to perform, especially when compared with the most
commonly used molecular procedures, such as polymerase
chain reaction (PCR) or real-time PCR. Even though these
methods are widespread, the high costs involved and the
need for highly skilled and trained operation makes them
difficult to implement at point-of-care and in remote
regions or low-resource countries. The AuNP based
methodologies that have already reached the clinical setting
may help solve this issue. Even though a large number of
methodologies and techniques have been presented for the
detection of DNA/RNA through AuNPs, most have done so
in controlled experimental settings and/or using synthetic or
previously prepared molecules as targets. Few methods
have been applied to the detection of DNA/RNA directly in
clinical samples; these are summarized in Table 1.
Conclusions and future trends
In the last few years use of AuNPs in clinical diagnosis has
developed rapidly and although effective application to
clinical samples and targets is still scarce much effort is
being devoted to bringing the use of these tools from the
laboratory to the clinic. A particularly promising application
of the colorimetric detection capabilities of AuNPs is based
in specific DNA-functionalized AuNPs (“Au-nanoprobes”)
for hybridization with a DNA target-analyte, allowing for a
Table 1 Methodologies based on spherical gold nanoparticles for detection of nucleic acid sequences (DNA/RNA) directly in clinical samples.
The underlying principle of the methods is listed, with limit of detection, molecular target (gene, locus, organism, etc) and type of sample
Detection Detection limit Clinical biological targets / sample Refs.
Naked-eye (dry-reagent dipstick) 2 fmol–25 fmola,b Hepatitis C virus (HCV) / RNA, human plasma
SNPs (mannose-binding lectin gene, MBL2) /
genomic DNA, human whole blood
[82, 83]
Naked-eye (electrostatic
interactions of unmodified AuNPs)
100 fmola SNPs associated with long QT syndrome—KCNE1




33 zmol Methicillin-resistant Staphylococcus aureus
and Staphylococcus epidermidis, (mecA gene) / DNA,
cultured bacteria
[51]




100 nmol L−1 a
K-ras oncogene / genomic DNA, colorectal
adenocarcinoma cell lines; β-thalassemia
mutations / genomic DNA, human whole blood




250 zmol–10 amol Coagulation genes (Factor V, Factor II, and MTHFR—
associated with thrombotic disease) / genomic DNA,
human placenta; Gene expression in human brain /
human brain total RNA; Methicillin-resistant
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rapid, sensitive and inexpensive detection system. These
systems have been successfully applied to the detection of
specific DNA and RNA sequences, mutations, and SNPs,
and to the detection of several pathogens. These strategies
could easily become the next generation of diagnostic tools,
as they show great sensitivity and specificity that can easily
replace conventional molecular methods such as PCR and
PCR-based approaches.
Furthermore, a recent nanotechnology development en-
abling extremely sensitive detection of biomolecules is the use
of AuNPs as sensitizing agents for microcantilever-based
sensors. Array systems are being developed with more than
one hundred cantilevers in parallel [79], enabling low
concentrations and small volumes to be probed with micro-
cantilevers [80]. However, the greatest improvement in
sensitivity to date has been through the use of nanoparticles
as mass enhancers, allowing detection of DNA at a
concentration of 23 pmol L−1 [81]. It is to be expected that
small, high-frequency cantilevers and sensitization with
metallic nanoparticles can enable sensitivity of microcanti-
lever-based biosensors to increase to the femtomolar range
and beyond, while maintaining the possibility of performing
parallel analyses and working with minute volumes.
Future trends of AuNPs in diagnostics encompass their
functionalization, allowing tailoring of the AuNP-biomolecule
interface and modulation of the properties of the biomolecule
either directly functionalized to the AuNP (e.g., thiolated DNA
segments) or adsorbed on a suitable surface. Promising
examples of the former are mixed monolayer-protected
clusters (MMPCs), Au-nanoprobes with specific chemical
functionalities that can be used in a “chemical nose/tongue”
array to detect, identify, and quantify protein targets [3], and
the glyconanotechnology strategy that holds great potential
for utilization in clinical diagnosis [36], as it allows for the
establishment of carbohydrate-mediated interactions, a highly
relevant type of interaction in biological systems.
Although significant advances have been made involving
the use of Au-NPs for diagnostics applications, technical and
practical problems need to be solved. These include tight
control over particle synthesis (size, size dispersion, capping
agents) and functionalization, as small variations can
drastically change their properties and behavior in diagnostic
methods. One should note that most of the proposed systems
must still be taken from proof-of-concept to use in
generalized laboratorial settings, and from there to common
clinical and diagnostic situations. Many questions on sample
handling and preparation still need to be addressed, as many
of these Au-NP systems are rather unstable in complex
media, which may hinder application at point-of-care.
Further developments should include convenient high-
throughput analysis, either by multiplexing and use of
instrumentation, or by means of different chemistry that
may vary the physicochemical properties of the AuNPs.
Additional advances will be directed towards creation of
integrated platforms to test for a variety of analytes
simultaneously without loss of sensitivity, providing fast,
specific, and low cost analysis at point-of-care. This could
bring from bench to bedside instruments that will enable
faster screening of alterations (DNA associated with human
pathology, gene expression profiles, biochemical analysis,
and pathogen identification), enabling tailored therapeutic
intervention, prevention, and reduction of the significant
number of hospital admissions that results from therapeutic
incompatibility and failure.
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